DANIEL B. SOLAND - 01 Apr 2022 Form 4 Insider Report for IDERA PHARMACEUTICALS, INC.

Role
CHIEF OPERATING OFFICER
Signature
/s/ Daniel B. Soland
Issuer symbol
N/A
Transactions as of
01 Apr 2022
Net transactions value
$0
Form type
4
Filing time
04 Apr 2022, 17:43:45 UTC
Previous filing
26 Jan 2022
Next filing
09 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDRA Stock Option (Right to Buy) Award $0 +41,500 $0.000000 41,500 01 Apr 2022 Common Stock 41,500 $0.5350 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on January 24, 2026, with 25% vesting on January 24, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer.